Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer

See Locations Near You

Summary

This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Confirmed SCLC with known UGT1A genotype.
Patients who have received at least 1 prior platinum-based chemotherapy.
Life expectancy of 3 months or more.
Measurable disease.

Exclusion Criteria:

Patients with UGT1A polymorphism.
Currently receiving chemotherapy.
Pregnant and nursing women.

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

10

Study ID:

NCT04173325

Recruitment Status:

Terminated

Sponsor:

Augusta University

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Georgia Cancer Center at AU Medical Center
Augusta Georgia, 30912, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

10

Study ID:

NCT04173325

Recruitment Status:

Terminated

Sponsor:


Augusta University

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider